ArticleFrontiers in cellular and infection microbiology2026
Investigating the diversity of intratumoral microbiota in high-grade serous ovarian cancer with varying platinum sensitivity.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer remains the most lethal gynecological malignancy. However, no studies have investigated the differences in intratumoral microbiota among patients with varying platinum sensitivity. This study aims to explore the intratumoral microbiota of ovarian cancer in relation to different sensitivities to platinum-based chemotherapy. Methods: Tumor samples were collected from ovarian cancer patients exhibiting different platinum-sensitive statuses and subjected to microbiome (16S rRNA gene sequencing) analyses. Following DNA extraction and PCR amplification, library construction and sequencing were performed. The differences in intratumoral microbiota across various groups were analyzed both individually and collectively using a range of bioinformatics approaches. Results: A total of 22 patients with high-grade serous ovarian cancer participated in this study, including 6 from the platinum-sensitive recurrent group, 8 from the platinum-resistant recurrent group, and 8 from the platinum-refractory group. Bacterial diversity within the intratumoral microbiota, phylogenetic profiles of microbial communities, as well as functional predictions and bacterial phenotypes all exhibited significant differences among these three groups. At the phylum level, Firmicutes, Actinobacteria, and Acidobacteria were significantly more abundant in the platinum-refractory group compared to both the platinum-sensitive recurrent group and the platinum-resistant recurrent group. Additionally, genera Lactococcus and Corynebacterium showed significant enrichment in the platinum-refractory group relative to both other groups. Conclusions: This study is pioneering in identifying variations in intratumoral microbiota associated with differing sensitivities to platinum therapy in ovarian cancer patients; these findings may provide valuable insights for future mechanistic research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.